Absci (NASDAQ:ABSI – Get Free Report) will likely be posting its quarterly earnings results after the market closes on Tuesday, March 18th. Analysts expect Absci to post earnings of ($0.23) per share ...

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and ...

VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company ...

Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates ...

VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company ...

VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating ...

CAMBRIDGE, United Kingdom, March 04, 2025 (GLOBE NEWSWIRE) -- Mestag Therapeutics ("Mestag”), a biotech company harnessing ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Absci Co. (NASDAQ:ABSI – Get Free Report) has been given an average rating of “Buy” by the seven analysts that are presently covering the company, Marketbeat Ratings reports. Seven research analysts ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

"As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it's leveraging AI." Sean McClain, founder and CEO of Absci, and Christian Stegmann, SVP of ...